European Primary Care Cardiovascular Society
Data of US postmenopausal women with normal BMI show that trunk fat and higher leg fat have opposing associations with CVD risk, while total body fat was not significantly related to CVD risk.
ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.
ESC 2019 Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidaemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.
ESC 2019 The first data in the FH Studies Collaboration registry show that among 42,000 adults with heterozygous FH, about half of patients received a statin and the majority was not at LDL-c goal.
ESC 2019 Using genetic scores to assess lifelong exposure to LDL-c and SBP levels, suggests that relatively small differences in this exposure associated large proportional risk reductions.
ESC 2019 The guidelines emphasize that the absolute LDL-C reduction drives the clinical benefit. Evidence suggests a benefit of treating earlier, which may mean less intensive therapy in the longer-term.
Observational population-based study suggests that continuing statin therapy after the age of 75 years may reduce CV risk in persons taking the medication for primary prevention.
EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.
EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.
Based on a large Dutch primary care database, lipid-lowering treatment declined with increasing age in subjects aged ≥70 years, with higher prescription in frail vs. non-frail older adults regardless of CVD at baseline.
EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.
EAS 2019 An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.
